PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies (Q42704491)

5 November 2017

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies (English)

1 reference

5 November 2017

3

1 reference

5 November 2017

7

1 reference

5 November 2017

8

1 reference

Hildegard Kehrer-Sawatzki

5 November 2017

10

object named as

Hildegard Kehrer-Sawatzki

1 reference

5 November 2017

9

Victor Mautner

1 reference

5 November 2017

Thomas De Raedt

1

1 reference

5 November 2017

Eline Beert

2

1 reference

5 November 2017

Armelle Luscan

4

1 reference

5 November 2017

Hilde Brems

5

1 reference

5 November 2017

Nicolas Ortonne

6

1 reference

5 November 2017

Wade Clapp

11

1 reference

5 November 2017

James Bradner

12

1 reference

5 November 2017

Michel Vidaud

13

1 reference

5 November 2017

Meena Upadhyaya

14

1 reference

5 November 2017

Eric Legius

15

1 reference

5 November 2017

Karen Cichowski

16

1 reference

5 November 2017

language of work or name

English

0 references

publication date

13 August 2014

1 reference

5 November 2017

1 reference

5 November 2017

514

1 reference

5 November 2017

7521

1 reference

5 November 2017

247-251

1 reference

https://scigraph.springernature.com/pub.10.1038/nature13561

5 November 2017

0 references

cites work

Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Stage-specific sensitivity to p53 restoration during lung cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Selective activation of p53-mediated tumour suppression in high-grade tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

The RasGAP gene, RASAL2, is a tumor and metastasis suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Genomic organization and evolution of the NF1 microdeletion region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Elevated risk for MPNST in NF1 microdeletion patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Mouse models of tumor development in neurofibromatosis type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Histone recognition and large-scale structural analysis of the human bromodomain family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Selective inhibition of BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Targeting MYCN in neuroblastoma by BET bromodomain inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

TORC1 is essential for NF1-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Tumour predisposition in mice heterozygous for a targeted mutation in Nf1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE13561

TP53 mutations are frequent in malignant NF1 tumors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25119042

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Recombination hotspot in NF1 microdeletion patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25119042

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NATURE13561

1 reference

Dimensions Publication ID

5 November 2017

0 references

1 reference